Definium Therapeutics (DFTX) Cash from Financing Activities (2019 - 2026)

Definium Therapeutics (DFTX) has 7 years of Cash from Financing Activities data on file, last reported at $5.3 million in Q1 2026.

• Cash from Financing Activities for Q1 2026 came in at $5.3 million, up 429.84% year-over-year; the trailing twelve-month figure through Mar 2026 was $271.6 million (up 219.69% YoY), and the FY2025 annual result was $267.3 million, up 5.56% from the prior year.
• Cash from Financing Activities eased to $5.3 million in Q1 2026 per DFTX's latest filing, from $245.9 million in the prior quarter.
• Over five years, Cash from Financing Activities peaked at $245.9 million in Q4 2025 and troughed at -$166000.0 in Q1 2022.
• A 5-year average of $35.7 million and a median of $3.8 million in 2024 frame the typical range for Cash from Financing Activities.
• The sharpest annual moves came in 2022 and 2024: Cash from Financing Activities slumped 100.18% in 2022, then surged 28930.36% in 2024.
• A 5-year view of Cash from Financing Activities shows it stood at $416000.0 in 2022, then surged by 523.32% to $2.6 million in 2023, then soared by 46.82% to $3.8 million in 2024, then surged by 6358.31% to $245.9 million in 2025, then plunged by 97.84% to $5.3 million in 2026.
• Business Quant data shows DFTX's Cash from Financing Activities at $5.3 million in Q1 2026, $245.9 million in Q4 2025, and $749000.0 in Q3 2025.